{
  "docId": "019de073-7a8f-7069-abd7-4f5a253312a5",
  "docSlug": "7534f8dddd85d538a9efc95a5aebf002",
  "documentTitle": "Aquestive Therapeutics | Results Presentation Deck | 14 slides",
  "authorId": "aquestive-therapeutics",
  "authorName": "Aquestive Therapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 9,
  "pageCount": 14,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 40,
  "notes": "Shows rapid onset of therapeutic benefits for AQST-109.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7a8f-7069-abd7-4f5a253312a5/9",
  "deckHref": "/decks/019de073-7a8f-7069-abd7-4f5a253312a5",
  "deckJsonHref": "/decks/019de073-7a8f-7069-abd7-4f5a253312a5.json",
  "deckAnchorHref": "/decks/019de073-7a8f-7069-abd7-4f5a253312a5#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.43,
        "x": 0.52,
        "y": 0.365
      },
      "kind": "chart",
      "text": "Mean Baseline Adjusted Pulse over 130 minutes by Treatment EPIPHAST II, Single Administration Treatments",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fd859e5-85e7-4d7e-8b7c-8bd8bd085f4e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.43,
        "x": 0.06,
        "y": 0.365
      },
      "kind": "chart",
      "text": "Mean Baseline Adjusted SBP over 130 minutes by Treatment EPIPHAST II, Single Administration Treatments",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69738f1d-501c-409a-96df-4f541bd731c3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.06,
        "y": 0.26
      },
      "kind": "list",
      "text": "AQST-109 demonstrates a pharmacodynamic response for Systolic Blood Pressure (SBP) and Pulse consistent with that of EpiPen. Pronounced early peak in PD implies rapid and robust onset of therapeutic benefits",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e988c0aa-54c8-4798-b0f2-d6b1de2522d2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.07,
        "y": 0.19
      },
      "kind": "title",
      "text": "EPIPHAST II: Pharmacodynamic (PD) Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d8aeb37-2047-468b-97c7-91fa365647cb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "c6210b0a-fa9b-4f9e-b103-2b409df65982",
      "evidence": "The slide presents a clear narrative arc of pharmacodynamic results, showcasing the efficacy of AQST-109.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 3,
      "beatId": "fd64535f-8805-4be0-ab9c-f0396589752f",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document provides relief through presentation of EPIPHAST II trial results, including key takeaways and data, on slides 3-13",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 10,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "b6791be9-182b-48c3-8ddb-65cec4fe9e39",
      "evidence": "The document implies the cost of inaction through presentation of rapid epinephrine delivery and trial results",
      "position": 0,
      "objective": "What is the cost of not using Aquestive Therapeutics' epinephrine product?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}